Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-02-16 00:00:00 ET · period of report 2023-02-14 · accession 0001209191-23-010055 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-02-16 | 2023-02-14 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $300.39 | -2,181 | 60.0K | -4% | -$655.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-14 | S | D | 279 | $301.11 | 59,734 | D | — | — | (F4) Open market sales reported on this line occurred at a weighted average price of $301.11 (range $301.02 to $301.22). (F2) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2023-02-14 | S | D | 1,902 | $300.29 | 60,013 | D | — | — | (F2) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F3) Open market sales reported on this line occurred at a weighted average price of $300.29 (range $300.00 to $300.92). |